ReviewDrugs2023
Targeting IL-23 for IBD: Rationale and Progress to Date.
Review in Drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- EFFECTIVENESS AND SAFETY OF SELECTIVE IL-12/23 RECEPTOR ANTAGONISTS IN MODERATE TO SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW, META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS.Arquivos de gastroenterologia · 2026Pooled it
- Efficacy and safety of IL-23p19 antagonists versus placebo in inflammatory bowel disease: a systematic review and meta‑analysis of randomized controlled trials.International journal of clinical pharmacy · 2025Pooled it
- Comparing the Efficacy of Advanced Interleukin Inhibitors for Crohn's Disease: A Systematic Review and Network Meta-Analysis.Journal of clinical medicine · 2026Review
- Inequities in inflammatory bowel disease care: a Tasmanian case study with proposed solutions.Internal medicine journal · 2026Review
- Advancing IBD Management: A Literature Review on the Role of Non-Invasive Blood-Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment.Clinical and translational science · 2026Review
- When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Efficacy and safety of risankizumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2026Article
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse.Frontiers in immunology · 2026Review
- Autoimmune disease risk gene ANKRD55 promotes TH17 effector function through metabolic modulation.The Journal of experimental medicine · 2025Article
- EngineeredActa pharmaceutica Sinica. B · 2025Article
- IL-23 promotes neuronal ferroptosis via IL-23R/STAT3 signaling after traumatic brain injury.Cell communication and signaling : CCS · 2025Article
- Review
- Novel Cyclic Peptides as Interleukin-23 Inhibitor for Treating Inflammatory Disorders.ACS medicinal chemistry letters · 2025Article
- Multimodal profiling of transplant rejection: Discerning the forest from the trees.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025Article
- New Interleukin-23 Antagonists' Use in Crohn's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Sometimes Small Is Beautiful: Discovery of the Janus Kinases (JAK) and Signal Transducer and Activator of Transcription (STAT) Pathways and the Initial Development of JAK Inhibitors for IBD Treatment.Digestive diseases and sciences · 2025Review
- Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies.Journal of clinical medicine · 2025Review
- Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD.Digestive diseases and sciences · 2025Review
- Advances in understanding the role of interleukins in pulmonary fibrosis (Review).Experimental and therapeutic medicine · 2025Review
- Guselkumab binding to CD64Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, comprises multiple complex immune-mediated disorders. Early diagnosis and prompt disease control may prevent long-term complications and hospitalization. The therapeutic options have expanded in the last two decades, with the development of biologics and small molecules targeting specific pathways implicated in inflammatory bowel disease pathogenesis. The interleukin (IL)-23/Th-17 axis is one such example. Targeting IL-12/23 is effective for the treatment of both moderate-to-severe Crohn's disease and ulcerative colitis, and ustekinumab (an IL-12/23p40 antagonist) is approved for both indications. In patients with psoriasis, improved clinical outcomes were observed with agents that more selectively targeted IL-23 (IL-23p19 antagonists) compared with those that target both IL-12 and IL-23. Many specific IL-23p19 antagonists are currently being investigated in Crohn's disease and ulcerative colitis, and risankizumab has been recently approved for moderate-to-severely active Crohn's disease. In this review, we summarize the mechanisms of action and the evidence from clinical trials supporting the efficacy and safety of IL-23p19 antagonists for the treatment of inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.